FindTrial
Sign In

A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer.

A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001159-12-IT
Enrollment
Unknown
Registered
2009-05-13
Start date
2004-10-15
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly patients affected by advanced colorectal cancer MedDRA version: 6.1 Level: PT Classification code 10010035

Interventions

Trade Name: ELOXATIN*IV 1FL POLV 100MG Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Oxaliplatin CAS Number: 61825-94-3 Concentration unit: mg milligram(s) Concentration type: equal C

Sponsors

AZIENDA OSPEDALIERA S. CARLO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026